Pfizer beats Q3 expectations but sales teeter

29th October 2014

Pfizer managed to beat performance expectations for the third quarter, as results were given a leg up by solid demand in emerging markets (up 9%) and strong sales of its cancer drugs, which grew 17%

The drug giant booked earnings of $2.67 billion, or $0.42 a share for the period, inching up from $2.59 billion, or $0.39 per share, a year ago, though last year’s standing was pulled down by restructuring costs.

drug giant booked earnings of $2.67 billion, or $0.42 a share for the period, inching up from $2.59 billion, or $0.39 per share, a year ago, though last year’s standing was pulled down by restructuring costs.

Read more at: http://www.pharmatimes.com/Article/14-10-28/Pfizer_beats_Q3_expectations_but_sales_teeter.aspx#ixzz3HXpQwsB2
Follow us: @PharmaTimes on Twitter

Read more at source article: www.pharmatimes.com

 

Pfizer managed to beat performance expectations for the third quarter, as results were given a leg up by solid demand in emerging markets (up 9%) and strong sales of its cancer drugs, which grew 17%

Read more at: http://www.pharmatimes.com/Article/14-10-28/Pfizer_beats_Q3_expectations_but_sales_teeter.aspx#ixzz3HXpQwsB2
Follow us: @PharmaTimes on Twitter


Leave a Reply

Your email address will not be published.

− 3 = 2

« back to posts